

WEST Search History

DATE: Friday, October 15, 2004

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND</i>		
<input type="checkbox"/>	L1	salmonella same chlamyd\$	2194
<input type="checkbox"/>	L2	L1.ti;ab,clm.	276
<input type="checkbox"/>	L3	L2 and (avirulent or a-virulent or mutant or mutation or attenuate or attenuation or attenuat\$ or modifi\$ or alter\$ or gene or genetic\$ or vector)	194
<input type="checkbox"/>	L4	L2 same (avirulent or a-virulent or mutant or mutation or attenuate or attenuation or attenuat\$ or modifi\$ or alter\$ or gene or genetic\$ or vector)	32
	<i>DB=USPT,PGPB,JPAB,EPAB; PLUR=YES; OP=AND</i>		
<input type="checkbox"/>	L5	(US-6676949-B2)! [pn]	0
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND</i>		
<input type="checkbox"/>	L6	momp\$.clm.	29
<input type="checkbox"/>	L7	curtiss.in. and chlamyd\$.clm.	0
<input type="checkbox"/>	L8	chlamyd\$.clm.	774
<input type="checkbox"/>	L9	L8 and \$tiss.in.	1

END OF SEARCH HISTORY

-
- ☐ 14. 6500419. 07 Apr 00; 31 Dec 02. Method for introducing and expressing RNA in animal cells. Hone; David M., et al. 424/93.2; 424/93.1 435/252.3 435/320.1 435/455 514/44. A61K048/00 C12N001/21 C12N015/87.
-
- ☐ 15. 6150170. 30 Jul 98; 21 Nov 00. Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same. Powell; Robert J., et al. 435/455; 424/184.1 424/93.1 424/93.21 424/93.4 435/320.1 435/472 435/480 435/69.1 514/44. C12N015/63 C12N015/00 C12N005/00 A01N043/04 A61K031/70.
-
- ☐ 16. 5877159. 03 May 95; 02 Mar 99. Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same. Powell; Robert J., et al. 514/44; 424/184.1 424/93.1 424/93.21 424/93.4 435/235.1 435/320.1 435/472 435/480 435/69.1 536/24.1. A01N043/04 A61K031/70 C12N015/63.
-
- ☐ 17. 4861709. 31 May 85; 29 Aug 89. Detection and/or identification of microorganisms in a test sample using bioluminescence or other exogenous genetically-introduced marker. Ulitzur; Shimon Y., et al. 435/6; 435/14 435/170 435/18 435/19 435/21 435/25 435/26 435/261 435/29 435/32 435/34 435/36 435/38 435/5 435/8 435/822 536/23.2. C12Q001/68 C12Q001/66 C12Q001/02 C12Q001/04.
-
- ☐ 18. US20030134274A. Detecting nucleic acid in sample comprises hybridizing nucleic acid to probe that comprises crosslinking agent forming covalent crosslink between probe and nucleic acid and detecting crosslinked nucleic acid pair. ALBAGLI, D, et al. C07H021/00 C12Q001/68 C12Q001/70.
-
- ☐ 19. US 6495676B. Detecting target nucleic acid, by hybridizing target to crosslinkable probe with a complementary polynucleotide and crosslinking group, activating group to crosslink probe and target, detecting crosslinked pair. ALBAGLI, D, et al. C07H021/00.
-
- ☐ 20. WO 200286154A. Novel genetically labeled bacteriophage for use in prophylactic and therapeutic treatment of bacterial infections in plants, livestock, birds and humans, and for environmental clean up and sanitation. ALLAIN, B, et al. C12Q001/68.
-
- ☐ 21. WO 200283216A. Drug delivery device containing a substance e.g. drug is used for the intradermal injection of the substance into the skin of an animal. ALARCON, J B, et al. A61K039/145 A61K045/00 A61M005/28 A61M005/32 A61M005/46.
-
- ☐ 22. US20020137233A. Optically active polymer useful as biopathogen or bacterial sensor, comprises diacetylene unit at center of hydrophobic core, glutamic acid headgroup on one hydrophilic end and oxy acid end group on other end. CHENG, Q, et al. C12Q001/70 G01N033/544 G01N033/545.
-
- ☐ 23. GB 2370838A. Immunogenic complex useful as vaccine for treating diseases caused by microbes, e.g. Escherichia coli, Candida or diseases caused by periodontal bacteria, has at least one ribosomal complex and adhesin of a microbe. TIMMERMAN, B. A61K039/00 A61K039/02 A61K039/38 A61P031/04 C07H021/02 C07K014/195 C07K017/00.
-
- ☐ 24. US20020064517A. Transformation of cells with nucleic acid for use in gene therapy, comprises administering nucleic acid to a cell and applying a fibrin gel to entrap the nucleic acid. CEDERHOLM-WILLIAMS, S A. A61K009/06 A61K035/00 A61K039/00 A61K039/39 A61K039/395 A61K047/42 A61K048/00 C12N015/09 C12N015/11 C12N015/63.
-
- ☐ 25. WO 200034498A. Vaccination against diseases caused by Chlamydia infection involves initial

administration of attenuated bacteria containing nucleic acid encoding Chlamydia protein, followed by administration of Chlamydia protein. BRUNHAM, R C, et al. A61K031/70 A61K035/74 A61K035/76 A61K038/00 A61K039/00 A61K039/02 A61K039/112 A61K039/118 A61K039/38 A61K048/00 A61P015/00 A61P027/02 A61P031/04 C12N001/20 C12N001/21 C12N001:21 C12N015/09 C12N015/31 C12N015/86 C12N015/87 C12Q001/68 C12R001:42 C12N001/21 C12R001:42 C12R001:42 C12N001/21.

☐ 26. WO 200018949A. Composition used to facilitate uptake of aminoglycoside antibiotic into cells comprises phosphoinositide polyphosphate and/or inositol polyphosphate and polyamine. DEWALD, D B, et al. A61F002/00 A61F013/00 C12Q000/00.

☐ 27. WO 200018434A. New mutant cholera holotoxin having a point mutation at amino acid position 29 of the A subunit useful as an adjuvant in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen from a pathogen. ELDRIDGE, J H, et al. A61K039/00 A61K039/002 A61K039/02 A61K039/095 A61K039/102 A61K039/106 A61K039/12 A61K039/15 A61K039/155 A61K039/245 A61K039/39 A61P037/04 C07K014/14 C07K014/22 C07K014/28 C07K014/285 C07K014:28 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/63 C12P021/02.

☐ 28. WO 200014240A. Attenuated gram-negative Salmonella cells, comprising inactivated genes in the SPI2 locus and useful for vaccinating against a range of disorders associated with microbial infections such as stomach and cervical cancers. APFEL, H, et al. A61K039/00 A61K039/106 A61K039/112 A61K039/12 A61K039/245 A61K039/29 A61K048/00 A61P031/04 A61P031/12 A61P035/00 C07K014/005 C07K014/195 C07K014/255 C07K014/47 C07K016/12 C07K019/00 C12N001/21 C12N001:21 C12N007/00 C12N015/09 C12N015/31 C12N015/62 C12N015/63 C12N015/74 C12R001:42 C12N001/21 C12N001/21 C12N001/21 C12R001:01 C12R001:42 C12R001:63 C12R001:42 C12N001/21.

☐ 29. US 6001556A. Polymeric assay film for direct colorimetric detection of small molecules such as pathogens. CHARYCH, D, et al. C12Q001/70.

☐ 30. US 6342352B. New bacterial proteins useful for preparing vaccines for treating bacterial infections, especially shigellosis. MAURELLI, A T, et al. A61K039/02 A61K039/112 A61K039/395 C12N015/82 C12Q001/02 C12Q001/04 C12Q001/68 G01N033/53 G01N033/532 G01N033/554 G01N033/569.

☐ 31. WO 9838320A. New isolated bromelain component protein - used for e.g. treating cancers, immuno: deficiency(s) or diseases which respond to increased nitric oxide production or as a vaccine adjuvant or antimicrobial agent. ENGWERDA, C, et al. A61K038/46 A61K038/48 A61K039/39 A61P003/10 A61P017/02 A61P031/04 A61P031/18 A61P033/06 A61P035/00 A61P037/04 A61P043/00 C07H000/00 C07K000/00 C12N000/00 C12N009/50 C12N015/09 C12N015/57.

☐ 32. DE 19639601A. Parapox virus strain D1701 HindIII fragment I, related recombinant viruses and expression plasmids - useful in vaccines, for expression of foreign DNA and for diagnosis. BUTTNER, M, et al. A61K035/76 A61K038/00 A61K039/00 A61K039/275 A61K048/00 A61P037/02 A61P043/00 C07H021/04 C07K014/065 C12N000/00 C12N007/00 C12N007/01 C12N007/04 C12N015/09 C12N015/11 C12N015/39 C12N015/63 C12N015/86 C12N015/863 G01N033/569 C12N015/09 C12R001:92.

Generate Collection

Print

Terms	Documents
L2 same (avirulent or a-virulent or mutant or mutation or attenuate or attenuation or attenuat\$ or modifi\$ or alter\$ or gene or genetic\$ or vector)	32

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

Your wildcard search against 10000 terms has yielded the results below.

Your result set for the last L# is incomplete.

The probable cause is use of unlimited truncation. Revise your search strategy to use limited truncation.

Generate Collection

Print

Search Results - Record(s) 1 through 32 of 32 returned.

- ☐ 1. 20040152099. 17 Nov 03. 05 Aug 04. Screening method for attenuating or virulence defective microbial cells. Freissler, Elke, et al. 435/6; C12Q001/68.
- ☐ 2. 20040137011. 01 Jul 03. 15 Jul 04. Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance. Cunningham, Phillip R.. 424/190.1; 424/191.1 435/320.1 A61K039/02 A61K039/002 C12N015/74.
- ☐ 3. 20040136963. 19 Dec 03. 15 Jul 04. Simian adenovirus vectors and methods of use. Wilson, James M., et al. 424/93.2; 435/456 A61K048/00 C12N015/861.
- ☐ 4. 20040025866. 01 Aug 03. 12 Feb 04. Drug delivery system including holder and drug container. Vedrine, Lionel, et al. 128/200.19; B05B007/00 A61M011/00.
- ☐ 5. 20030203473. 20 Nov 02. 30 Oct 03. Microbial SUMO protease homologs. Godzik, Adam, et al. 435/252.3; 536/23.1 C07H021/02 C07H021/04 C12N001/20.
- ☐ 6. 20030153527. 21 Feb 03. 14 Aug 03. Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same. Powell, Robert J., et al. 514/44; 435/252.3 435/252.33 435/455 A61K048/00 C12N001/21 C12N015/85.
- ☐ 7. 20020193778. 08 Feb 02. 19 Dec 02. Method of intradermally injecting substances. Alchas, Paul G., et al. 604/506; 604/187 A61M031/00.
- ☐ 8. 20020193740. 10 Jan 02. 19 Dec 02. Method of intradermally injecting substances. Alchas, Paul G., et al. 604/117; 604/507 A61M031/00.
- ☐ 9. 20020038111. 13 Apr 01. 28 Mar 02. Method of intradermally injecting substances. Alchas, Paul G., et al. 604/500; 604/187 604/522 606/172 A61M005/00 A61M031/00.
- ☐ 10. 20020022718. 19 Dec 00. 21 Feb 02. Genes identified as required for proliferation of E. coli. Forsyth, R. Allyn, et al. 536/23.1; 435/183 435/325 435/6 435/69.1 C07H021/02 C07H021/04 C12Q001/68 C12N009/00 C12P021/02 C12N005/06.
- ☐ 11. 20020010428. 10 Apr 01. 24 Jan 02. Drug delivery system including holder and drug container. Vedrine, Lionel, et al. 604/187; A61M005/00.
- ☐ 12. 6689118. 08 Feb 02; 10 Feb 04. Method of intradermally injecting substances. Alchas; Paul G., et al. 604/506; 604/117. A61M031/00.
- ☐ 13. 6569143. 13 Apr 01; 27 May 03. Method of intradermally injecting substances. Alchas; Paul G., et al. 604/506; 604/117. A61M031/00.

[Previous Doc](#) [Next Doc](#) [Go to Doc#](#)
[First Hit](#) [Fwd Refs](#)



Generate Collection

ODP

L6: Entry 16 of 29

File: USPT

Jan 13, 2004

DOCUMENT-IDENTIFIER: US 6676949 B2

TITLE: Two-step immunization procedure against Chlamydia infection

CLAIMS:

1. A method of immunizing a host, which comprises: initially administering to the host an attenuated bacteria harbouring a vector comprising a nucleic acid molecule encoding a major outer membrane protein (MOMP) of a strain of Chlamydia and a promoter sequence operatively coupled to said nucleic acid molecule for expression of said MOMP of a strain of Chlamydia in cells of the host but not in said attenuated bacteria, and subsequently administering to the host a purified major outer membrane protein (MOMP) of a strain of Chlamydia.

6. The method of claim 1 wherein said MOMP of a strain of Chlamydia in said subsequent administration step is administered incorporated into an immunostimulating complex (ISCOM).

11. A method of immunizing a host, which comprises: initially administering to the host an attenuated bacterial harbouring a vector comprising a nucleic acid molecule encoding a major outer membrane protein (MOMP) of a strain of Chlamydia and a promoter which is a cytomegalovirus promoter operatively coupled to said nucleic acid molecule for expression of said MOMP of a strain of Chlamydia in cells of the host, and subsequently administering to the host a purified major outer membrane protein (MOMP) of a strain of Chlamydia.

12. A method of immunizing a host, which comprises: initially administering to the host an attenuated bacteria harbouring a plasmid vector which is pcDNA3/MOMP as seen in FIG. 5, and subsequently administering to the host a purified major outer membrane protein (MOMP) of a strain of Chlamydia.

[Previous Doc](#) [Next Doc](#) [Go to Doc#](#)